REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Total Voting Rights and Block Listing Return

MaxCyteAnnouncement

02/12/2024 17:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241202:nRSB4816Oa&default-theme=true

RNS Number : 4816O  MaxCyte, Inc.  02 December 2024

MaxCyte, Inc.

 

("MaxCyte" or the "Company")

 

Total Voting Rights and Block Listing Return

 

ROCKVILLE, MD, December 2, 2024: MaxCyte Inc., (Nasdaq: MXCT; LSE: MXCT), a
leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and commercialization of
next-generation cell-based therapeutics and innovative bioprocessing
applications, announces that pursuant to its block admission facility, since
31 October 2024 it has issued 256,320 of common stock, $0.01 par, of the
Company ("Common Stock") in satisfaction of the exercise of share options
and/or vesting of restricted stock units.

Total voting rights

As at 30 November 2024, the total issued stock capital of the Company
following the recent issue of the new Common Stock is 105,691,189 shares of
Common Stock. Shareholders in the Company may use this figure as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
stock capital of the Company.

Block Listing Return

 

MaxCyte also makes the following notification pursuant to AIM Rule 29 and
Schedule Six of the AIM Rules for Companies, regarding its existing block
listings:

 

 Name of applicant:                                                                MaxCyte, Inc.
 Name of scheme:                                                                   MaxCyte Long Term Incentive Plan
 Period of return:                        From:                                    2 April 2024         To:                  2 December 2024
 Balance of unallotted securities under scheme(s) from previous return:            9,038,342 ordinary shares of common stock at $0.01 each
 Plus:  The amount by which the block scheme(s) has been increased since the       Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         1,416,648 ordinary shares of common stock at $0.01 each
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        7,621,694 ordinary shares of common stock at $0.01 each

 

 Name of contact:              Douglas Swirsky, Chief Financial Officer
 Telephone number of contact:  +1 301 944 1700

 

 

For further information, please contact:

 

    MaxCyte Contacts:

    US IR Adviser                                 +1 415-937-5400

    Gilmartin Group                               ir@maxcyte.com

    David Deuchler, CFA

    Nominated Adviser and Joint Corporate Broker

    Panmure Liberum                               +44 (0)20 7886 2500

    Emma Earl / Freddy Crossley

    Corporate Broking

    Rupert Dearden

    UK IR Adviser                                 +44 (0)203 709 5700

    ICR Healthcare                                maxcyte@icrhealthcare.com

    Mary-Jane Elliott

    Chris Welsh

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or disposables; and
software protocols, all supported by a robust worldwide intellectual property
portfolio. By providing our partners with the right technology platform, as
well as scientific, technical, and regulatory support, we aim to guide them on
their journey to transform human health. Learn more at maxcyte.com
(https://maxcyte.com/)  and follow us on X and LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFZMGZVZNGDZM